CAP TODAY/AstraZeneca Webinar: Homologous Recombination Deficiency (HRD) Testing in Advanced Ovarian Cancer

Thank you

This live web event has ended. Thank you for attending.

Description

Homologous Recombination
Deficiency (HRD) Testing in
Advanced Ovarian Cancer

Why should you register now for this webinar?

Learn the role of homologous recombination deficiency (HRD) in the development of ovarian cancer
Explore the rationale for expanded biomarker testing in advanced ovarian cancer
Discuss strategies to maximize testing efficiency with pathologist-initiated testing

Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenters: Dana Chase, MD, FACOG and Shirley Michelle Shiller, DO, MSPT
You will have the opportunity to ask questions to our distinguished presenters.

CAP TODAY does not endorse any of the products or services named within. This webinar is sponsored by AstraZeneca. ©2020 AstraZeneca. All rights reserved. US-44039 Last Updated 8/20

Contributors

Bob McGonnagle

Publisher, CAP TODAY
Dana Chase, MD, FACOG

Assistant Professor,
Division of Gynecologic Oncology
University of Arizona College of Medicine, Phoenix, AZ
Creighton University School of Medicine
at St. Joseph’s Hospital, Phoenix, AZ
Gynecologic Oncologist, Arizona Oncology
(US Oncology Network), multiple locations
Shirley Michelle Shiller, DO, MSPT

Co-Medical Director
Division of Molecular Medicine and Pathology
Baylor Sammons Cancer Center
Baylor University Medical Center
Dallas, Texas